The Latin America, Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Market would witness market growth of 7.3% CAGR during the forecast period (2022-2028).
The rise in the prevalence of cardiovascular illnesses, the increased risk of organ failure, and the development of innovative congestive heart failure treatment devices by a significant number of heart failure device businesses are driving the CHF treatment devices market. A considerable number of people all over the world require a heart transplant after a certain age. As a result, the rising number of patients with heart failure has raised the demand for ventricular assist devices, which is expected to fuel market expansion and provide opportunities for congestive heart failure treatment devices.
Furthermore, an increase in the geriatric population has raised the number of cardiovascular disease patients, and a shortage of organ donors is one of the main factors driving growth in the congestive heart failure treatment devices market. The market is expected to develop as the burden of cardiovascular illnesses rises and the prevalence of heart failure increases. Additionally, the growing number of product approvals is likely to give lucrative prospects for the congestive heart failure therapy devices market players.
In the United Arab Emirates (UAE), cardiovascular disease was the main cause of death among women in 2010. Because heart attacks are more common in older women, indications of heart disease may be concealed by symptoms of chronic conditions, which could explain why women delay seeking medical help and have a greater death rate after an ischemic incident. There were various research and development programs across the region in order to raise awareness of heart disease among Emirati women and to better understand how Emirati women seek healthcare in the UAE. Cardiovascular diseases (CVD) kill more people in this region than any other disease, as per the World Health Organization. Moreover, the prevalence of CVDs are also very high among adult women as a considerable number of adult women across this region died from CVD in recent years.
The Brazil market dominated the LAMEA Congestive Heart Failure (CHF) Treatment Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $294.5 Million by 2028. The Argentina market is poised to grow at a CAGR of 7.9% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 7% during (2022 - 2028).
Based on Product Type, the market is segmented into Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Congestive Heart Failure (CHF) Treatment Devices Market is Predict to reach $16.5 Billion by 2028, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
